Phase I Study: Itraconazole Effect on Pharmacokinetics of HS-10506

ClinicalTrials.gov has added registration for Phase I trial NCT07535970, a single-center study evaluating the effect of itraconazole (CYP3A inhibitor) on the pharmacokinetics of HS-10506 tablets in healthy Chinese adult participants. The study uses a fixed-sequence, self-controlled design with two interventions: HS-10506 and itraconazole.

For pharmaceutical sponsors and clinical investigators, this trial registration signals ongoing drug interaction research involving CYP3A enzyme inhibition and represents a standard Phase I clinical study entry in the NIH registry. The registration provides transparency regarding upcoming clinical research but does not create compliance obligations for regulated entities.